Intellia Therapeutics Inc (OQ:NTLA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 40 Erie St Ste 130
CAMBRIDGE MA 02139-4254
Tel: 1-857-7061612
IR: See website
Key People
John M. Leonard
President, Chief Executive Officer, Director
Glenn G. Goddard
Chief Financial Officer, Executive Vice President, Treasurer
Andrew D. Schiermeier
Chief Operating Officer, Executive Vice President
Laura Sepp-Lorenzino
Executive Vice President, Chief Scientific Officer
James Basta
Executive Vice President, General Counsel, Corporate Secretary
David Lebwohl
Executive Vice President, Chief Medical Officer
Business Overview
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
Financial Overview
For the three months ended 31 March 2021, IntelliaTherapeutics Inc revenues decreased 50% to $6.4M. Net lossincreased 45% to $46.2M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsResearch & Development - Balancing value increase of 10% to$35.8M (expense), General and administrative - Balancingincrease of 14% to $10.7M (expense).
Employees: 312 as of Feb 19, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $9,633M as of Mar 31, 2021
Annual revenue (TTM): $51.52M as of Mar 31, 2021
EBITDA (TTM): -$143.60M as of Mar 31, 2021
Net annual income (TTM): -$148.63M as of Mar 31, 2021
Free cash flow (TTM): -$68.90M as of Mar 31, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 72,028,265 as of Jun 29, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.